诊断学理论与实践 ›› 2020, Vol. 19 ›› Issue (03): 214-218.doi: 10.16150/j.1671-2870.2020.03.002
游利
收稿日期:2020-02-05
出版日期:2020-06-25
发布日期:2020-06-25
基金资助:
Received:2020-02-05
Online:2020-06-25
Published:2020-06-25
中图分类号:
游利. 重视骨转换指标的临床应用及评估[J]. 诊断学理论与实践, 2020, 19(03): 214-218.
图1
骨转换指标的监测与评估流程[6] BMD:骨密度(bone mineral density);BTMs:骨转换指标 (bone turnover markers)
| [1] | 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5):413-443. |
| [2] | 中华医学会骨质疏松和骨矿盐疾病分会. 骨代谢生化标志物临床应用指南[J]. 中华骨质疏松和骨矿盐疾病杂志, 2015, 8(4):283-293. |
| [3] |
Szulc P, Delmas PD. Biochemical markers of bone turnover in men[J]. Calcif Tissue Int, 2001, 69(4):229-234.
doi: 10.1007/s00223-001-1059-1 URL |
| [4] |
Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation[J]. Osteoporos Int, 2000, 11(Suppl 6):S2-S17.
doi: 10.1007/s001980070002 URL |
| [5] |
Greenblatt MB, Tsai, JN; Wein, MN. Bone turnover mar-kers in the diagnosis and monitoring of metabolic bone disease[J]. Clin Chem, 2017, 63(2):464-474.
doi: 10.1373/clinchem.2016.259085 pmid: 27940448 |
| [6] | 廖二元, 徐苓, 朱汉民, 等. 原发性骨质疏松症干预的疗效监测与评估专家意见[J]. 中华骨质疏松和骨矿盐疾病杂志, 2015, 8(1):1-6. |
| [7] | Jain S, Camacho P. Use of bone turnover markers in the management of osteoporosis[J]. Curr Opin Endocrinol Dia-betes Obes, 2018, 25(6):366-372. |
| [8] |
Glendenning P, Chubb SAP, Vasikaran S. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults[J]. Clin Chim Acta, 2018, 481:161-170.
doi: S0009-8981(18)30125-6 pmid: 29544749 |
| [9] |
Sowers MR, Zheng H, Greendale GA, et al. Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity[J]. J Clin Endocrinol Metab, 2013, 98(7):2854-2863.
doi: 10.1210/jc.2012-4113 URL |
| [10] |
Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis[J]. J Bone Miner Res, 1996, 11(3):337-349.
pmid: 8852944 |
| [11] |
Vilaca T, Gossiel F, Eastell R, et al. Bone turnover markers: Use in fracture prediction[J]. J Clin Densitom, 2017, 20(3):346-352.
doi: 10.1016/j.jocd.2017.06.020 URL |
| [12] |
Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study[J]. J Bone Miner Res, 2005, 20(10):1813-1819.
pmid: 16160738 |
| [13] |
Johansson H, Odén A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture[J]. Calcif Tissue Int, 2014, 94(5):560-567.
doi: 10.1007/s00223-014-9842-y URL |
| [14] |
Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women[J]. J Bone Miner Res, 2004, 19(3):386-393.
pmid: 15040826 |
| [15] |
Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial[J]. J Bone Miner Res, 2004, 19(8):1250-1258.
doi: 10.1359/JBMR.040512 URL |
| [16] |
Ivaska KK, Gerdhem P, Akesson K, et al. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women[J]. J Bone Miner Res, 2007, 22(8):1155-1164.
pmid: 17488197 |
| [17] |
Moghaddam A, Müller U, Roth HJ, et al. TRACP 5b and CTX as osteological markers of delayed fracture healing[J]. Injury, 2011, 42(8):758-764.
doi: 10.1016/j.injury.2010.11.017 pmid: 21168135 |
| [18] | Marchelli D, Piodi LP, Corradini C, et al. Increased serum OPG in atrophic nonunion shaft fractures[J]. J Orthop Trau-matol, 2009, 10(2):55-58. |
| [19] |
Yoon BH, Yu W. Clinical utility of biochemical marker of bone turnover: Fracture risk prediction and bone hea-ling[J]. J Bone Metab, 2018, 25(2):73-78.
doi: 10.11005/jbm.2018.25.2.73 URL |
| [20] |
Blumsohn A, Marin F, Nickelsen T, et al. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide[J]. Osteoporos Int, 2011, 22(6):1935-1946.
doi: 10.1007/s00198-010-1379-y pmid: 20938767 |
| [21] |
Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate[J]. J Bone Miner Res, 2003, 18(6):1051-1056.
pmid: 12817758 |
| [1] | 上海交通大学医学院附属瑞金医院肺小结节诊治和管理学科群专家组. 肺结节活检术风险管理瑞金专家共识[J]. 诊断学理论与实践, 2022, 21(01): 22-31. |
| [2] | 杨晓辰, 朱圆, 孙琼, 余小萍, 张娴. 主观认知下降的影响因素、评估与干预研究新进展[J]. 诊断学理论与实践, 2022, 21(01): 90-94. |
| [3] | 陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528. |
| [4] | 李海. 慢加急肝衰竭的诊断标准及管理[J]. 诊断学理论与实践, 2021, 20(05): 434-438. |
| [5] | 叶晨静, 张弦, 周淑颖, 张晨莉, 龚艳春, 童建菁, 阎骅. 操作技能直接观察评估考核在全科住院医师规范化培训中的应用及效果评价[J]. 诊断学理论与实践, 2021, 20(03): 311-313. |
| [6] | 陈信光, 张凤祥. 特定人群室性心律失常风险评估进展及策略[J]. 诊断学理论与实践, 2020, 19(06): 549-554. |
| [7] | 刘彤, 王鑫. 心房颤动预后不良风险的评估策略[J]. 诊断学理论与实践, 2020, 19(06): 555-558. |
| [8] | 丁凤鸣, 周妍, 田雪, 廖若敏, 张杏怡. 胜任力模型在呼吸与危重症医学科进修医师培训中的应用[J]. 诊断学理论与实践, 2020, 19(02): 203-205. |
| [9] | 马文明, 李强, 卓然, 冒永鑫, 戴军, 罗艳, 孙福康. 嗜铬细胞瘤术前CT影像学参数与围手术期参数的相关性研究[J]. 诊断学理论与实践, 2020, 19(02): 172-176. |
| [10] | 陈辰, 张月, 胡晓波. 尿路感染报警信息阈值设置和临床应用评价[J]. 诊断学理论与实践, 2020, 19(02): 168-171. |
| [11] | 余红, 王一飞, 陈佳, 陈洁, 李斌. 青蒿素及其衍生物在皮肤疾病中的作用机制研究及临床应用[J]. 诊断学理论与实践, 2019, 18(2): 233-236. |
| [12] | 毛毅敏, 黄伸伸, 和雪改. 围手术期静脉血栓栓塞症形成风险评估及抗凝药物管理[J]. 诊断学理论与实践, 2019, 18(1): 16-20. |
| [13] | 蒋荣珍, 钱智敏. 子痫前期的预测、预防研究现状及进展[J]. 诊断学理论与实践, 2019, 18(06): 605-712. |
| [14] | 林建华, 缪慧娴. 妊娠合并心脏病的分类诊断和妊娠风险评估[J]. 诊断学理论与实践, 2019, 18(06): 613-618. |
| [15] | 李欣欣, 肖淑珍, 谭希婧, 倪语星, 韩立中. 评估新型奈瑟嗜血杆菌药敏试剂盒测试流感嗜血杆菌药敏结果[J]. 诊断学理论与实践, 2019, 18(05): 526-531. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
